Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02960022 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 78 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv78
  2. Enrollment closed, study ongoing Trial sites reduced: 241 → 234 locationsv77 Show 1 more changeShow less
    • Trial sites reduced: 241 → 234 locations
  3. Site details revised at 4 of 241 sitesv76
  4. Eligibility criteria expanded, about 13 words Study description expanded, about 7 words · Site details revised at 1 of 241 sitesv75 Show 2 more changesShow less
    • Study description expanded, about 7 words
    • Site details revised at 1 of 241 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 240 to 241v74
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 236 to 240v73
  2. Primary and study completion dates: Jul 31, 2026 to Jul 31, 2029 Study description expanded, about 35 wordsv72 Show 1 more changeShow less
    • Study description expanded, about 35 words

    See this version in full on ClinicalTrials.gov ↗

  3. Interventions: abiraterone acetate (Drug), enzalutamide (Drug), prednisone (Drug) to Leuprolide acetate (Drug), abiraterone acetate (Drug), enzalutamide (Drug), prednisone (Drug) Site details revised at 4 of 236 sites · Study arms: 2 to 3v71 Show 2 more changesShow less
    • Site details revised at 4 of 236 sites
    • Study arms: 2 to 3
  4. Site details revised at 7 of 236 sitesv70
  5. Site details revised at 3 of 236 sitesv69
  6. Site details revised at 2 of 236 sitesv68
  7. Study sites: 235 to 236v67
  8. Study sites: 234 to 235v66
  9. Re-verified, no change to tracked fieldsv65
  10. Site details revised at 3 of 234 sitesv64
  11. Study sites: 233 to 234v63
  12. Study sites: 226 to 233v62
  13. Study sites: 221 to 226v61
  14. Site details revised at 8 of 221 sitesv60
  15. Study sites: 212 to 221v59
  16. Study sites: 199 to 212v58
  17. Study sites: 191 to 199v57
  18. Study sites: 182 to 191v56
  19. Study sites: 179 to 182v55
  20. Study sites: 173 to 179v54
  21. Primary and study completion dates: Sep 30, 2025 to Jul 31, 2026 Site details revised at 3 of 173 sitesv53 Show 1 more changeShow less
    • Site details revised at 3 of 173 sites
  22. Study sites: 163 to 173v52
  23. Study sites: 161 to 163v51
  24. Study sites: 156 to 161v50
  25. Study sites: 151 to 156v49
  26. Study sites: 148 to 151v48
  27. Study sites: 147 to 148v47
  28. Study sites: 144 to 147v46
  29. Study sites: 142 to 144v45
  30. Study sites: 140 to 142v44
  31. Study sites: 139 to 140v43
  32. Study sites: 138 to 139v42
  33. Re-verified, no change to tracked fieldsv41
  34. Primary and study completion dates: Nov 30, 2024 to Sep 30, 2025 Study sites: 132 to 138v40 Show 1 more changeShow less
    • Study sites: 132 to 138
  35. Study sites: 130 to 132v39
  36. Study sites: 127 to 130v38
  37. Study sites: 122 to 127v37
  38. Site details revised at 1 of 122 sitesv36
  39. Re-verified, no change to tracked fieldsv35
  40. Site details revised at 1 of 122 sitesv34
  41. Site details revised at 5 of 122 sitesv33
  42. Study Status, Study Description, Arms and Interventionsv32
  43. 2 versions Re-verified since Nov 29, 2021, no change to tracked fieldsv30-v31
  44. Site details revised at 9 of 122 sitesv29
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Trial Details
NCT Number NCT02960022
Lead Sponsor Astellas Pharma Global Development, Inc.
Collaborators: Pfizer
Conditions Prostate Cancer
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov